Preoperative Planning With PSMA-PET in Melanoma Surgery Trial

Recruiting now · Phase 2

Conditions studied: Malignant Melanoma

In brief

This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.

Key facts

Study ID

NCT06560905

Run by

Royal Marsden NHS Foundation Trust

People needed

16

Starts

2025-03-11

Expected to finish

2025-12-31

Last updated by the study team

2025-07-01

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Males ≥18 years of age
• Biopsy proven first and recurrent metastatic melanoma with palpable nodal disease who have undergone a staging FDG PET-CT scan as part of routine clinical care and are scheduled for surgery for resection of the primary site

You may not qualify if…

• Patients unable to give voluntary written informed consent to participate in this study
• Patients not willing to complete all the study assessments
• Patients who are females
• Patients who are taking androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists.
• Patients who have or have previously been diagnosed with prostate cancer
• Patients who have had Lu-177 PSMA therapy or barium studies within a period of 10 days prior to undergoing PSMA PET-CT scanning
• Patients not fluent in English

Where it is running

• The Royal Marsden NHS Foundation Trust — London, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.